SNK 863

Drug Profile

SNK 863

Alternative Names: Recel; SK 863

Latest Information Update: 10 Sep 1997

Price : $50

At a glance

  • Originator Sanwa Kagaku Kenkyusho
  • Developer NK Curex; Sanwa Kagaku Kenkyusho
  • Class
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Skin ulcer

Most Recent Events

  • 10 Sep 1997 No-Development-Reported for Skin ulcer in Japan (Topical)
  • 15 Dec 1995 Preregistration for Skin ulcer in Japan (Topical)
  • 14 Dec 1995 A study has been added to the therapeutics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top